Pharma-grade longevity
Pharma-grade longevity, powered by nature and AI.
Nanyang Biologics Holdings is a pharma-grade longevity company integrating deep technology with molecular innovation across AI drug discovery, therapeutics, and nutraceuticals.
Our Mission
To unlock meaningful health and wellness solutions by transforming nature's insights through science, technology, and innovation.
Holdings structure
Nanyang Biologics Holdings
NYB AI
Advances drug discovery through a proprietary AI-led platform inspired by nature.
The platform analyses biological, chemical, and botanical data to accelerate the identification of novel therapeutic leads.
Read moreNYB Therapeutics
Develops early-stage therapies guided by biology, data, and nature.
Our programmes focus on metabolic health, inflammation, and oncology.
Read moreNYB Nutraceuticals
Develops clinically guided, nature-derived formulations.
Each formulation combines plant-based science, safety, and cultural knowledge to support wellness.
Read more
Key metrics
- Compound library
- 2B+
- Natural compounds
- 10M+
- Higher hit rate
- 64x
- Bioactivity prediction efficiency
- 44.83%
Virtually screenable molecules accessible through our AI pipeline.
Plant-derived bioactives indexed for screening.
Improvement over the most popular molecular docking software.
Increase reported in our IEEE DTIGN paper versus baseline.
Platform
From 2B compounds to clinical candidates.
Our DTIGN model — a drug-target interaction graph neural network published on IEEE Xplore — powers a screening stack that has demonstrated a 64x hit-rate uplift over the most popular molecular docking software.
Read the scienceSolid Tumor (HRD)
NB-A001
Pre-clinical
Solid Tumor (HRD)
NB-A002
Clinical Phase I
Solid Tumor (HRD)
NB-A007
Pre-clinical
Solid Tumor (HRD)
NB-B101
Pre-clinical
Solid Tumor (HRD)
NB-B102
Pre-clinical
Solid Tumor (HRD)
NB-B107
Pre-clinical
Newsroom
Latest research & milestones
Conference
Nanyang Biologics Reflects on NVIDIA GTC 2026: A Week of Discovery, Dialogue, and Momentum
NYB at GTC 2026 with valuable scientific exchange, external feedback, and cross-sector dialogue.
22 Mar 2026
Conference
Nanyang Biologics to Exhibit at NVIDIA GTC 2026
Nanyang Biologics is pleased to announce that we will be exhibiting at NVIDIA GTC 2026, taking place from March 16–19, 2026.
10 Feb 2026
Publication
Introducing LigoSpace: Advancing Bioactivity Prediction at NeurIPS 2025
Nanyang Biologics is excited to share that its latest research, LigoSpace, developed in collaboration with Nanyang Technological University Singapore (NTU), has been presented at NeurIPS 2025, one of the world's most prestigious conferences in AI and ML.
12 Dec 2025
Research Briefs
Subscribe to NYB Research Briefs
Monthly digest of our AI drug discovery progress, publications, and longevity science.